Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600062's Return-on-Tangible-Equity is ranked better than 79.89% of 900
companies
in the Drug Manufacturers industry
Industry Median: 7.925
vs SHSE:600062: 20.42
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
China Resources Double-Crane Pharmaceutical Co Return-on-Tangible-Equity Related Terms
China Resources Double-Crane Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co Return-on-Tangible-Equity Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
SHSE:600062 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 23.45% mean?
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Return-on-Tangible-Equity of 23.45% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is 37% above median its historical median of 17.16. Over the past decade, China Resources Double-Crane Pharmaceutical Co's Return-on-Tangible-Equity has ranged from 13.32 to 21.86. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #181 out of 900 companies in the Drug Manufacturers industry, placing it in the top 20.1%.
Is China Resources Double-Crane Pharmaceutical Co's Return-on-Tangible-Equity too high?
China Resources Double-Crane Pharmaceutical Co's current Return-on-Tangible-Equity of 23.45% is 37% above median its 10-year median of 17.16. Over the past 10 years, this metric has ranged from a low of 13.32 to a high of 21.86. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.93. China Resources Double-Crane Pharmaceutical Co's value of 23.45% is 195.9% above this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #181 out of 900 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #181 out of 900 companies for Return-on-Tangible-Equity. This places China Resources Double-Crane Pharmaceutical Co in the top 20% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.93. China Resources Double-Crane Pharmaceutical Co's value of 23.45% is 195.9% above this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own Return-on-Tangible-Equity has ranged from 13.32 to 21.86 over the past decade. While the company's 10-year median is 17.16 vs. the industry median of 7.93, China Resources Double-Crane Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.93, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current Return-on-Tangible-Equity of 23.45% is 195.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current Return-on-Tangible-Equity is 23.45%, which is 37% above median its own 10-year median of 17.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.81, compared to a current price of ¥16.93 — trading 10% below its estimated fair value. The current Return-on-Tangible-Equity is 23.45%, which is 37% above median its 10-year median of 17.16 and 195.9% above the Drug Manufacturers industry median of 7.93. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Return-on-Tangible-Equity is 23.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥16.93 is trading 10% below its estimated GF Value™ of ¥18.81.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
Return-on-Tangible-Equity: 23.45% (37% above median its 10-year median of 17.16)
GF Value™: ¥18.81 vs. price of ¥16.93 (10% below fair value)
Industry Position: 195.9% above the Drug Manufacturers median (#181 of 900)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Business Description
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score
Get the complete analysis for SHSE:600062
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
